title: Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women.
abstract: Acceleration of bone remodelling increases the risk of fragility fractures. The objective of the present study was to explore in elderly women whether a vitamin D and Ca-fortified dairy product providing about 17-25 % of the recommended intakes in vitamin D, Ca and proteins would reduce secondary hyperparathyroidism and bone remodelling in a way that may attenuate age-related bone loss in the long term. Thirty-seven institutionalised women, aged 84.8 (sd 8.1) years, with low serum 25-hydroxyvitamin D (5.5 (sd 1.7) ng/ml) were enrolled into a multicentre open trial to consume during 1 month two servings of soft plain cheese made of semi-skimmed milk providing daily 686 kJ (164 kcal), 2.5 microg vitamin D, 302 mg Ca and 14.2 g proteins. The primary endpoint was the change in serum carboxy terminal cross-linked telopeptide of type I collagen (CTX), selected as a marker of bone resorption. Thirty-five subjects remained compliant. Mean serum changes were: 25-hydroyvitamin D, +14.5 % (P = 0.0051); parathyroid hormone (PTH), - 12.3 % (P = 0.0011); CTX, - 7.5 % (P = 0.01); tartrate-resistant acid phosphatase isoform 5b (TRAP 5b), - 9.9 % (P < 0.0001); albumin, +6.2 % (P < 0.0001); insulin-like growth factor-I (IGF-I),+16.9 % (P < 0.0001); osteocalcin, +8.3 % (P = 0.0166); amino-terminal propeptide of type 1 procollagen (P1NP),+19.3 % (P = 0.0031). The present open trial suggests that fortified soft plain cheese consumed by elderly women with vitamin D insufficiency can reduce bone resorption markers by positively influencing Ca and protein economy, as expressed by decreased PTH and increased IGF-I, respectively. The rise in the bone formation marker P1NP could be explained by a protein-mediated increase in IGF-I. Thus, such a dietary intervention might uncouple, at least transiently, bone resorption from bone formation and thereby attenuate age-related bone loss.
authors.affiliation: WHO Collaborating Center for Osteoporosis Prevention, University Hospitals, Geneva, Switzerland. jean-philippe.bonjour@unige.ch
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Bonjour
authors.forename: Valérie
authors.initials: V
authors.lastname: Benoit
authors.forename: Olivier
authors.initials: O
authors.lastname: Pourchaire
authors.forename: Monique
authors.initials: M
authors.lastname: Ferry
authors.forename: Brigitte
authors.initials: B
authors.lastname: Rousseau
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000097:blood / Q000517:prevention & control*; D002136:Calcium, Dietary / Q000008:administration & dosage / Q000627:therapeutic use*; D002611:Cheese / Q000032:analysis*; D024042:Collagen Type I / Q000097:blood; D005260:Female; D005527:Food, Fortified; D006707:Homes for the Aged; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000517:prevention & control; D009735:Nursing Homes; D010455:Peptides / Q000097:blood; D014807:Vitamin D / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000150:complications / Q000178:diet therapy; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D015415:Biomarkers; D002136:Calcium, Dietary; D024042:Collagen Type I; D010455:Peptides; D014815:Vitamins; C052929:collagen type I trimeric cross-linked peptide; D014807:Vitamin D; C104450:25-hydroxyvitamin D